BioGenes now offers anti-drug antibodies against Adalimumab and Infliximab (polyclonal and monoclonal) as well as pre-qualified immunogenicity and PK ELISAs for Adalimumab and Infliximab biosimilar studies.
Our custom services include:
- Development of monoclonal (for PK ELISA) or polyclonal (as control for immunogenicity studies) antibodies against your biosimilar, including production and pair search
- Development and qualification of PK and immunogenicity ELISAs, based on our optimized technology
Our preferred partner for validation and sample determination is Eurofins Munich. However, a transfer of the ELISA to you, or your CRO is possible.
Please find more information here: